Sarepta Therapeutics

Sarepta Therapeutics logo
🇺🇸United States
Ownership
Private, Public
Established
1980-01-01
Employees
1.3K
Market Cap
$13.4B
Website
http://www.sarepta.com
Introduction

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid

Phase 1
Completed
Conditions
First Posted Date
2006-09-27
Last Posted Date
2009-07-08
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT00381433
Locations
🇺🇸

NW Kinetics, Tacoma, Washington, United States

Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid

Phase 1
Completed
Conditions
First Posted Date
2006-06-22
Last Posted Date
2009-07-08
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
6
Registration Number
NCT00343148
Locations
🇺🇸

NW Kinetics, Tacoma, Washington, United States

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

First Posted Date
2005-11-03
Last Posted Date
2007-02-08
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
50
Registration Number
NCT00248066
Locations
🇩🇪

Cardiology Clinic, University Hospital of Essen, Essen, Germany

🇩🇪

Coburg Hospital - Cardiology Clinic, Coburg, Germany

🇩🇪

University Hospital of Heidelberg, Cardiology Clinic, Heidelberg, Germany

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

First Posted Date
2005-10-27
Last Posted Date
2008-04-10
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
40
Registration Number
NCT00244647

Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients

Phase 1
Terminated
Conditions
First Posted Date
2005-09-30
Last Posted Date
2008-04-10
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
80
Registration Number
NCT00229749

An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease

Phase 1
Terminated
Conditions
First Posted Date
2004-09-21
Last Posted Date
2009-07-08
Lead Sponsor
Sarepta Therapeutics, Inc.
Target Recruit Count
50
Registration Number
NCT00091845
© Copyright 2024. All Rights Reserved by MedPath